Express Scripts Holding (Nasdaq: ESRX) reported earnings on May 10. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Express Scripts Holding beat expectations on revenues and missed estimates on earnings per share.

Compared to the prior-year quarter, revenue increased and GAAP earnings per share dropped.

Gross margins grew, operating margins contracted, and net margins dropped.

Revenue details
Express Scripts Holding notched revenue of $12.13 billion. The 18 analysts polled by S&P Capital IQ foresaw net sales of $11.48 billion on the same basis. GAAP reported sales were 9.4% higher than the prior-year quarter's $11.09 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $0.73. The 22 earnings estimates compiled by S&P Capital IQ forecast $0.77 per share. GAAP EPS of $0.55 for Q1 were 9.8% lower than the prior-year quarter's $0.61 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 6.9%, 20 basis points better than the prior-year quarter. Operating margin was 4.7%, 30 basis points worse than the prior-year quarter. Net margin was 2.2%, 70 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $25.99 billion. On the bottom line, the average EPS estimate is $0.87.

Next year's average estimate for revenue is $91.39 billion. The average EPS estimate is $3.64.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 698 members out of 741 rating the stock outperform, and 43 members rating it underperform. Among 186 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 178 give Express Scripts Holding a green thumbs-up, and eight give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Express Scripts Holding is outperform, with an average price target of $61.75.

The health-care investing landscape is littered with also-rans and a few major winners. Is Express Scripts Holding prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.